Matthew V. Lorenzi

5.1k total citations
64 papers, 2.6k citations indexed

About

Matthew V. Lorenzi is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matthew V. Lorenzi has authored 64 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 22 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthew V. Lorenzi's work include Lung Cancer Treatments and Mutations (12 papers), Fibroblast Growth Factor Research (7 papers) and HER2/EGFR in Cancer Research (7 papers). Matthew V. Lorenzi is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Fibroblast Growth Factor Research (7 papers) and HER2/EGFR in Cancer Research (7 papers). Matthew V. Lorenzi collaborates with scholars based in United States, South Korea and Germany. Matthew V. Lorenzi's co-authors include Joshua C. Curtin, Toru Miki, Bruce Gomes, Gary Kasof, Derong Liu, Valérie Vivat‐Hannah, Sylvie Laquerre, F. Christopher Zusi, Sheri L. Moores and Barbara S. Bushey and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Matthew V. Lorenzi

62 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew V. Lorenzi United States	28	1.5k	920	586	421	367	64	2.6k
Atsushi Takano Japan	25	1.5k 1.0×	760 0.8×	473 0.8×	392 0.9×	332 0.9×	63	2.5k
Kevin G. Leong United States	15	1.9k 1.3×	1.3k 1.4×	544 0.9×	273 0.6×	638 1.7×	18	3.1k
Kaustubh Datta United States	33	2.0k 1.4×	827 0.9×	447 0.8×	350 0.8×	787 2.1×	75	3.1k
Hosein Kouros‐Mehr United States	21	1.8k 1.2×	1.3k 1.4×	572 1.0×	194 0.5×	532 1.4×	35	2.9k
Zhenhe Suo Norway	32	1.8k 1.2×	1.3k 1.4×	447 0.8×	273 0.6×	872 2.4×	107	3.1k
Marina Holgado-Madruga United States	24	2.4k 1.6×	1.1k 1.2×	293 0.5×	534 1.3×	378 1.0×	33	3.3k
Qunsheng Ji China	25	1.5k 1.0×	686 0.7×	538 0.9×	191 0.5×	560 1.5×	50	2.5k
Joseph M. Amann United States	28	1.8k 1.2×	825 0.9×	605 1.0×	173 0.4×	426 1.2×	53	2.7k
Choh Yeung United States	16	1.1k 0.8×	654 0.7×	656 1.1×	509 1.2×	290 0.8×	23	2.3k
Daniel J. Murphy United Kingdom	22	2.2k 1.5×	843 0.9×	306 0.5×	317 0.8×	645 1.8×	43	3.0k

Countries citing papers authored by Matthew V. Lorenzi

Since Specialization

Citations

This map shows the geographic impact of Matthew V. Lorenzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew V. Lorenzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew V. Lorenzi more than expected).

Fields of papers citing papers by Matthew V. Lorenzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew V. Lorenzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew V. Lorenzi. The network helps show where Matthew V. Lorenzi may publish in the future.

Co-authorship network of co-authors of Matthew V. Lorenzi

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew V. Lorenzi. A scholar is included among the top collaborators of Matthew V. Lorenzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew V. Lorenzi. Matthew V. Lorenzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smans, Karine, Katrin Sproesser, Kathryn Packman, et al.. (2024). 144 (PB132): JNJ-79032421 is a novel membrane restricted mesothelin targeting Tcell engaging bispecific antibody for treatment of mesothelin-positive cancers. European Journal of Cancer. 211. 114666–114666.

Vijayaraghavan, Smruthi, Lorraine Lipfert, Kristen Chevalier, et al.. (2020). Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Molecular Cancer Therapeutics. 19(10). 2044–2056. 138 indexed citations

Thompson, Jeffrey C., Wei‐Ting Hwang, Christiana Davis, et al.. (2019). Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer. 139. 1–8. 93 indexed citations

Park, K., Myung‐Ju Ahn, Min Hee Hong, et al.. (2018). OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S344–S345. 7 indexed citations

Karkera, Jayaprakash D., Dana Gaffney, Ademi Santiago-Walker, et al.. (2017). Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Molecular Cancer Therapeutics. 16(8). 1717–1726. 43 indexed citations

Brahmer, Julie R., Melissa L. Johnson, Mark M. Awad, et al.. (2017). P2.07-058 First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(11). S2151–S2151. 1 indexed citations

Moores, Sheri L., Mark L. Chiu, Barbara S. Bushey, et al.. (2016). A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors. Cancer Research. 76(13). 3942–3953. 188 indexed citations

Peng, Shaohua, Chad J. Creighton, Yiqun Zhang, et al.. (2013). Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. Journal of Translational Medicine. 11(1). 198–198. 55 indexed citations

Curtin, Joshua C. & Matthew V. Lorenzi. (2010). Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells. Oncotarget. 1(7). 563–577. 140 indexed citations

10.

Wan, Honghe, Tram Huynh, Suhong Pang, et al.. (2009). Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)—Hit to Lead studies. Bioorganic & Medicinal Chemistry Letters. 19(17). 5063–5066. 45 indexed citations

11.

Purandare, Ashok V., et al.. (2009). Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene. 28(24). 2305–2313. 25 indexed citations

12.

Kim, Soong‐Hoon, John S. Tokarski, Kenneth J. Leavitt, et al.. (2007). Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA. Bioorganic & Medicinal Chemistry Letters. 18(2). 634–639. 19 indexed citations

13.

Kellar, Kristen A., Matthew V. Lorenzi, Dan You, et al.. (2006). Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. Molecular Cancer Therapeutics. 5(6). 1571–1576. 5 indexed citations

14.

Fink, Brian E., Ashvinikumar V. Gavai, John S. Tokarski, et al.. (2006). Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorganic & Medicinal Chemistry Letters. 16(6). 1532–1536. 36 indexed citations

15.

Spires, Thomas, Brian E. Fink, Ellen K. Kick, et al.. (2005). Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3). The Prostate. 65(2). 159–170. 22 indexed citations

16.

Saito, Shinichi, Keiju Kamijo, Takashi Tatsumoto, et al.. (2004). Deregulation and Mislocalization of the Cytokinesis Regulator ECT2 Activate the Rho Signaling Pathways Leading to Malignant Transformation. Journal of Biological Chemistry. 279(8). 7169–7179. 105 indexed citations

17.

Saito, Shinichi, Takashi Tatsumoto, Matthew V. Lorenzi, et al.. (2003). Rho exchange factor ECT2 is induced by growth factors and regulates cytokinesis through the N‐terminal cell cycle regulator‐related domains. Journal of Cellular Biochemistry. 90(4). 819–836. 51 indexed citations

18.

Yamanaka, Ryuya, et al.. (2001). Ostip2, a Novel Oncoprotein that Associates with the Rho Exchange Factor Ost. DNA and Cell Biology. 20(7). 383–390. 1 indexed citations

19.

Lorenzi, Matthew V., et al.. (1997). Cooperative transformation of NIH3T3 cells by Gα12 and Rac1. Oncogene. 15(6). 727–735. 22 indexed citations

20.

Lorenzi, Matthew V., et al.. (1995). The Human Choline Acetyltransferase Gene Encodes Two Proteins. Journal of Neurochemistry. 65(2). 484–491. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact